The Presidency says Lenacapavir, a twice-yearly HIV prevention injection, will expand biomedical tools in South Africa’s fight against new infections and strengthen long-term public health interventions.

Limited supplies threaten potential positive effect of HIV prevention drug lenacapavir

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

The Presidency says Lenacapavir, a twice-yearly HIV prevention injection, will expand biomedical tools in South Africa’s fight against new infections and strengthen long-term…

President Cyril Ramaphosa is on Friday launching the rollout of Lenacapavir, a new injectable prevention for HIV/Aids.

President Cyril Ramaphosa has launched South Africa’s rollout of Lenacapavir, a twice-yearly HIV prevention injection aimed at reducing new infections and strengthening the…

A new twice-yearly HIV prevention injection could transform South Africa's fight against the epidemic — but U.S. aid cuts and limited doses threaten to slow its impact.

South Africa officially launched the national rollout of Lenacapavir, a groundbreaking, twice-yearly injectable drug for HIV prevention

South African officials on Friday announced that the HIV prevention drug Lenacapavir is now available there, calling it a "turning point."

South Africa's launch of Lenacapavir marks a transformative moment in the fight against HIV, promising to significantly reduce new infections and improve health outcomes for…

We look at how lenacapavir, a groundbreaking HIV prevention injection, is set to transform the fight against HIV and why it matters for millions worldwide.

Gauteng is set to roll out Lenacapavir, a new long-acting HIV prevention injection, targeting over 56,000 individuals at high risk of HIV infection.

A twice-yearly injectable HIV prevention drug has arrived in South Africa. The rollout of the drug, lenacapavir, is underway in the country that needs it the most, about…

In a potentially major advancement in the fight against HIV and AIDS, a South African laboratory is set to produce a generic version of a new preventive treatment that is…